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Anetoderma is characterized by a loss of normal elastic tissue that presents clinically as 
localized areas of wrinkled or flaccid skin. We describe the case of a 30-year-old 
woman with systemic lupus erythematosus-associated anetoderma and positive 
antiphospholipid antibodies. We discuss the possible role of these antibodies in the 
pathogenesis of anetoderma, and, when detected, the need to check for an associated 





We present the case of a 30-year-old woman with a 9-year history of systemic lupus 
erythematosus (SLE). At initial diagnosis, the patient met four of the 11 criteria of the 
American Rheumatism Association’s defining criteria for SLE: malar erythema, 
proteinuria in the context of membranous glomerulonephritis, positive anti-DNA 
antibodies (135 Ul⁄mL; normal range, 0–50 Ul⁄mL) and pleuropericardiac effusion. 
Investigations revealed negative anti-nuclear antibodies, complement C3 of 61 mg⁄dL 
(normal range, 80130 mg ⁄dL), C4 of 13.60 mg⁄dL (normal range, 15–30 mg⁄dL) and 
platelets of 195 (normal:150–350/pL). There was no history of spontaneous abortion, 
vascular thromboses, neurological disorders or heart valve defects. 
 
The patient consulted our Department with a 6-month history of asymptomatic ‘reddish’ 
lesions on the trunk and limbs. Physical examination revealed raised erythematous 
plaques on the trunk and limbs ranging from 1 to 4 cm in diameter. She also had other 
pink lesions of a similar size, which were raised and soft on palpation, on the trunk and 
arms (Fig. 1a and b). A skin biopsy specimen of the reddish plaques showed an 
epidermis with preservation of the basal layer and a perivascular lymphomonocytic 
infiltrate. There were no thromboses or signs of vasculitis. In the pink plaques, the 
lymphomonocytic infiltrate was less prominent. Direct immunofluorescence was 
performed on both types of lesion. Similar findings were observed: subepidermal linear 
deposits of IgA and granular deposits of IgG, IgM, C3 and C1q. In the blood vessels 
there were also IgM and C3 deposits (Fig. 2a). Orcein staining revealed loss of elastic 
fibres which was more evident in the softer plaque specimens (Fig. 2b). Despite the 
immunofluorescence findings there was no clinicopathological evidence for a 
subepidermal immunobullous disorder such as linear IgA disease or bullous 
pemphigoid. Neither was there any evidence of bullous SLE. Laboratory tests showed 
positive anti-cardiolipin antibodies and negative lupus anticoagulant. A diagnosis of 
SLE-associated anetoderma was made. The patient was treated with oral corticosteroids 
(deflazacort 12 mg⁄day), but without significant changes in the skin plaques. 
 
Anetoderma is an unusual disease of unknown aetiology. In its primary form, hormonal 
factors have been implicated, owing to its association with pregnancy and illnesses such 
as Addison’s disease.1 In other cases, an association with anti-Borrelia antibodies has 
been described.2 Stephansson et al. examined antiBorrelia antibodies in 14 patients but 
only one patient had an elevated IgM titre. However, three other patients had slightly 
elevated anti-Borrelia antibodies, although none of them had symptoms associated with 
Borrelia infection. Aside from endocrine or infections hypothesis, there has been 
increasing evidence for an immunological basis to anetoderma. Such ideas are 
supported by findings of immunoglobulin deposition on direct immunofluorescence 
(DIF) on anetoderma lesions, as well as by the known association of anetoderma with 
various autoimmune diseases. Hodak et al.3 reported six patients in whom DIF was 
positive at both the dermo-epidermal junction and within dermal blood vessels. 
Bergman et al.4 also described a subepidermal linear deposit similar to that noted in our 
patient. Furthermore, in some of the reported cases, immunoglobulin deposition around 
dermal collagen and elastic fibres was a feature. 
 
To our knowledge, the literature contains only 13 cases of patients with anetoderma 
associated with SLE.5 A key point has been that the association is not so much with 
lupus erythematosus as with the presence of antiphospholipid antibodies (APA).6 
Stephansson et al.2 observed that in a series of SLE patients, 15% of those with positive 
APA developed anetoderma, whereas none of those without these antibodies developed 
this skin condition. Similarly, patients with anetoderma have been described who did 
not develop lupus erythematosus, whereas they did have APA. Anetoderma might even 
be regarded as one further skin manifestation of anti-phospholipid syndrome, although 
not all patients with APA and anetoderma will develop this syndrome. 
  
What are the possible mechanisms through which these antibodies produce anetoderma? 
The findings in some skin biopsies of microthrombosis2,5,6 in patients with anetoderma 
and associated APA, have led some authors to consider that ischaemia of dermal tissues 
may trigger degeneration of elastic tissue.7,8 This pathological process may also be 
relevant in patients with lupus-related nephropathy, as renal function tends to deteriorate 
more quickly in APA-positive patients.9 It has also been suggested that the APA bind 
directly to the elastic fibres because of the presence of an antigen epitope that is 
phospholipid related, possibly apolipoprotein H.8 On the other hand, Skelton et al.10 
studied anetoderma in patients with HIV infection, and described how the anti-
cardiolipin antibodies might act by altering the mechanism of the inhibitors of certain 
dermal proteinases thereby favouring the destruction of elastic fibres. These authors, 
and others, maintain that the elastases from the inflammatory cells are responsible for 
the damage to the elastic fibres.2,8 Finally, the importance of disrupting inhibitors of 
proteolysis is highlighted in cases of patients with an alpha-1-anti-trypsin deficiency 
who also develop anetoderma.2 
 
In summary, in spite of the need to examine more cases to conclude if there is a 
significant association, we think it appropriate for all patients with anetoderma to be 
examined for autoimmune diseases and APAs in particular, as well as being followed 
and screened for the emergence of anti-phospholipid syndrome. 
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Figure 1. (a) Raised erythematous lesion on the neck. (b) Saccular anetoderma lesion 































Figure 2. (a) Direct immunofluorescence analysis revealed subepidermal linear deposits 
of IgA. In the blood vessels there was also IgM and C3 deposition. (b) Orcein staining, 
demonstrating few elastic fibres, consistent with anetoderma. 
